Testing for the breast-cancer susceptibility genes BRCA1 and BRCA2 is costly and not a standard screening tool for the general patient population.
The Komen Foundation's decisions to withdraw and then reinstate Planned Parenthood breast-screening funding highlight disturbing trends in health care.
Many expecting mothers' birth plans border on accusatory and convey a general sense of mistrust of the medical community.
Women are increasingly asking health care providers for help with their sex life.
Is genetic screening evolving into a commodity to help couples conceive designer babies?